Single infusion of CRISPR/Cas9‐edited sickle allele‐modified differentiated cluster (CD34+) hematopoietic stem progenitor cells (HSPC) in subjects with severe sickle cell disease (SCD) aged ≥12–35 years. Here, CD34 is linked to sickle cell disease.